Guia completo elaborado pelo Infectologista Dr. Ricardo Diaz sobre o perfil mutacional de todas as classes de ARV. Confira, neste segundo episódio, o perfil de resistência esperado na primeira falha aos ITRNN e IP. Para acessar o artigo na íntegra, clique aqui.
Referências
1. Munerato P, Sucupira MC, Oliveros MP, et al. HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of São Paulo, Brazil. AIDS Res Hum Retroviruses. 2010;26(3):265-73.
2. Meireles MV, Pascom ARP, Duarte EC, et al. Comparative effectiveness of first-line antiretroviral therapy: results from a large realworld cohort after the implementation of dolutegravir. AIDS. 2019;33(10):1663-8.
3. Ministério da Saúde. Protocolo clínico e diretrizes terapêuticas para manejo da infecção pelo hiv em adultos. 2018.
4. Zdanowicz MM. The pharmacology of HIV drug resistance. Am J Pharm Educ. 2006;70(5):100.
5. Parikh UM, Bacheler L, Koontz D, et al. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol. 2006;80(10):4971-7.
6. Deeks SG, Hoh R, Neilands TB, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug- -resistant HIV-1 infection. J Infect Dis. 2005;192(9):1537-44.
7. Bunupuradah T, Suntarattiwong P, Li A, et al.; HIV-NAT 013 Study Team. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors. Int J Infect Dis. 2010;14(4):e311-6.
8. Whitcomb JM, Huang W, Limoli K, et al. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS. 2002;16(15):F41-7.
9. Miller V, Phillips A, Rottmann C, et al. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine- -lamivudine combination therapy: association with therapy failure. J Infect Dis. 1998 Jun;177(6):1521-32.
10. Kagan RM, Lee TS, Ross L, et al. Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase. Antiviral Res. 2007;75(3):210-8.
11. Diaz RS. Should Tenofovir ever be used in association with ddI? Letter to the Editor. Brazilian J Infect Dis. 2005;9:452-3.
12. Lafeuillade A, Tardy JC. Stavudine in the face of cross-resistance between HIV-1 nucleoside reverse transcriptase inhibitors: a review. AIDS Rev. 2003;5(2):80-6.
13. Sax PE, Tierney C, Collier AC, et al.; AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361(23):2230-40.
14. Diaz RS. Potência e barreira genética dos medicamentos e esquemas antirretrovirais. Braz j infect dis. 2016;2(3):70-81.
15. Santos J, Palacios R, Lozano F, et al.; for the Grupo Andaluz Para el Estudio de las Enfermedades Infecciosas (GAEI). Long- -term assessment of didanosine, lamivudine, and efavirenz in antirretroviral-naive patients: 3-year follow-up. AIDS Res Hum Retroviruses. 2008;24(1):24-6.
16. Røge BT, Katzenstein TL, Obel N, et al. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther. 2003;8(2):173-82.
17. Gulick RM, Ribaudo HJ, Shikuma CM, et al.; AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350(18):1850-61.
18. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS. 2006;20(10):1391-9.
19. Arrivé E, Newell ML, Ekouevi DK, et al; Ghent Group on HIV in Women and Children. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol. 2007;36(5):1009-21.
20. Loubser S, Balfe P, Sherman G, et al. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS. 2006;20(7):995-1002.
21. Tambuyzer L, Vingerhoets J, Azijn H, et al. Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on na etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies. AIDS Res Hum Retroviruses. 2010;26(11):1197-205.
22. Smith SJ, Pauly GT, Akram A, et al. Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants. J Acquir Immune Defic Syndr. 2016;72(5):485-91.
23. Sanne I, Piliero P, Squires K, et al; AI424-007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose- -ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antirretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003;32(1):18-29.
24. Gardner EM, Burman WJ, Steiner JF, et al. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS. 2009;23(9):1035-46.
25. Colonno RJ, Thiry A, Limoli K, et al. Activities of atazanavir (BMS232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother. 2003;47(4):1324-33.
26. Gong YF, Robinson BS, Rose RE, et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS- -232632. Antimicrob Agents Chemother. 2000;44:2319-26.
27. Masquelier B, Assoumou KL, Descamps D, et al. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. J. Antimicrob. Chemother. 2008;61(6): 1362-8.
28. Zhang YM, Imamichi H, Imamichi T, et al. Drug Resistance during Indinavir Therapy Is Caused by Mutations in the Protease Gene and in Its Gag Substrate Cleavage Sites. J Virol. 1997;71(9):6662-70.
29. Colonno R, Rose R, McLaren C, et al. Identification of I50L as the Signature Atazanavir (ATV)-Resistance Mutation in -TreatmentNaive HIV-1-Infected Patients Receiving ATV-Containing Regimens. J Infec Dis. 2004;189(10):1802-10.
30. Ziermann R, Limoli K, Das K, et al. A Mutation in Human Immunodeficiency Virus Type 1 Protease, N88S, That Causes In Vitro Hypersensitivity to Amprenavir. J Virol. 2000;74(9):4414-9.
31. Maschera B, Darby G, Palú G, et al. Human Immunodeficiency Virus. J Bio Chem. 1996;271(52): 33231-5.
32. Bula de Elodius® (tipranavir). ANVISA.
33. Bethell R, Scherer J, Witvrouw M, et al. Short Communication phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in hiv from patients with discordant tipranavir and darunavir 14 susceptibility phenotypes. AIDS Research and Human Retroviruses. 2012;28(9):1019-24.
34. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006;368(9534):476-82.
35. Garriga C, Perez-Elias MJ, Delgado R. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. Med Virol. 2007;79(11):1617-28.
36. Kempf DJ, Isaacson JD, King MS. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol. 2001. 75(16):7462-9.
37. Mo H, King MS, King K. Selection of resistance in protease inhibitorexperienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol. 2005. 79(6):3329-38.
38. Barber TJ, Harrison L, Asboe D. Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother. 2012; 67(4):995-1000.
39. Santos JR, Llibre JM, Imaz A. Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens. J Antimicrob Chemother. 2012;67(6):1462-9.
40. Lambert-Niclot S, Masquelier B, Cohen Codar I. Impact of lopinavir/ ritonavir use on antiretroviral resistance in recent clinical practice. J Antimicrob Chemother. 201;67(10):2487-93.
41. Masquelier B, Breilh D, Neau D. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2002; 46(9):2926-32.
42. Paulsen D, Liao Q, Fusco G. Genotypic and phenotypic cross- -resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia. AIDS Res Hum Retroviruses. 2002;18(14):1011-9.
43. Meyer S, Vangeneugden T, van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses. 2008;24(3):379-88.
44. Bhat MA et al. Non-peptide protease inhibitors as novel antiHIV agents. Farmaceutica Sci. 2006;68(5):549-55.
45. Dierynck I, De Wit M, Gustin E, et al. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol. 2007;81:13845-51.
46. Clutter DS, Jordan MR, Bertagnolio S, et al. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016 Dec;46:292-307.
47. Clavel F. HIV resistance to raltegravir. Eur J Med Res. 2009; 14 Suppl 3:47-54.
48. Hardy I, Brenner B, Quashie P, et al. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. Journal of Antimicrobial Chemotherapy. 2015;70(2):405-11.
49. Quashie PK, Mesplède T, Han YS, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol. 2012;86(5):2696-705.
50. Rhee SY, Grant PM, Tzou PL, et al. A systematic review of the genetic mechanisms of dolutegravir resistance. J Antimicrob Chemother. 2019 Jul 5. pii: dkz256.
51. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor- -bound receptor for entry. J Virol. 2007;81(5):2359-71.
52. Lu J, Deeks SG, Hoh R, et al. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr. 2006;43:60-4.
53. Svicher V, Aquaro S, D’Arrigo R, et al. Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. J Infect Dis. 2008;197(10):1408-18.
54. Araújo LAL, Junqueira DM, Medeiros RM, et al. Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31 BC. J Clin Virol. 2012;54:6-10
Direitos Reservados - é proibida a reprodução e distribuição sem prévia autorização da Janssen-Cilag Farmacêutica. Material destinado exclusivamente à classe médica. CP-167389. Data de produção: Julho/2020.
CONTRAINDICAÇÕES: PREZISTA® é contraindicado em pacientes sensíveis ao darunavir ou a qualquer componente da fórmula do medicamento. Uso concomitante com medicamentos com depuração altamente dependente da CYP3Aastemizol, alfuzosina, colchicina (em pacientes com insuficiência renal e/ ou hepática), dapoxetina, dronedarona, elbasvir/grazoprevir, alcaloides do ergot (por exemplo: ergotamina, di-hidroergotamina, ergonovina e metilergonovina), ivabrandina, lomitamida, lovastatina, lurasidona, midazolam (oral), naloxegol, pimozida, ranolazina, sildenafila (quando usado no tratamento de hipertensão arterial pulmonar), sinvastatina, terfenadina e triazolam.
INTERAÇÕES MEDICAMENTOSAS: A coadministração de PREZISTA® e ritonavir com medicamentos metabolizados principalmente pela CYP3A, CYP2D6 ou transportado pela P-gp pode resultar concentrações plasmáticas aumentadas de tais medicamentos, o que pode aumentar ou prolongar seus efeitos terapêuticos e eventos adversos. O darunavir e o ritonavir são metabolizados pela CYP3A. Espera-se que os medicamentos que induzam a atividade da CYP3A, aumentem a depuração de darunavir e ritonavir, resultando em menores concentrações plasmáticas de darunavir e ritonavir. A coadministração com outros medicamentos que inibem a CYP3A pode diminuir a depuração de darunavir e ritonavir e pode resultar em concentrações plasmáticas aumentadas de darunavir e ritonavir. A administração concomitante com PREZISTA®/ritonavir pode resultar no aumento das concentrações plasmáticas do Anticoagulantes orais diretos (DOAC), o que pode levar a um aumento do risco de hemorragia. A co-administração de um DOAC afetado pela P-gp e CYP3A4, incluindo apixabana e rivaroxabana, não é recomendada com PREZISTA®/ritonavir.
Precisa de alguma informação ou tem alguma dúvida? Entre em contato com o INFOC: 0800 701 3017 ou infoc@janbr.jnj.com
Para relato de efeitos adversos: safe@jan.br.jnj.com
Fale conosco: 800 701 1851 ou sac@janbr.jnj.com
Para acessar a bula, clique aqui